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Spondylometaphyseal dysplasia with cone-rod dystrophy is a rare autosomal-recessive disorder characterized by severe short stature, pro-
gressive lower-limb bowing, flattened vertebral bodies, metaphyseal involvement, and visual impairment caused by cone-rod dystrophy.
Whole-exome sequencing of four individuals affected by this disorder from two Brazilian families identified two previously unreported
homozygousmutations in PCYT1A. This gene encodes the alpha isoform of the phosphate cytidylyltransferase 1 choline enzyme, which
is responsible for converting phosphocholine into cytidine diphosphate-choline, a key intermediate step in the phosphatidylcholine
biosynthesis pathway. A different enzymatic defect in this pathway has been previously associated with a muscular dystrophy with
mitochondrial structural abnormalities that does not have cartilage and/or bone or retinal involvement. Thus, the deregulation of
the phosphatidylcholine pathway may play a role in multiple genetic diseases in humans, and further studies are necessary to uncover
its precise pathogenic mechanisms and the entirety of its phenotypic spectrum.Spondylometaphyseal dysplasia with cone-rod dystrophy
(SMD-CRD [MIM 608940]) is a rare autosomal-recessive
condition that has been assigned to group 12 of the 2011
nosology and classification of skeletal diseases.1 It has
been reported in nine families and is characterized by
normal cognition, severe short stature, progressive bowing
of the lower limbs, platyspondyly, metaphyseal irregular-
ity, and cone-rod dystrophy causing visual impairment
(Table S1 available online).2–4 The genetic defect that
causes SMD-CRD is unknown.
We evaluated four Brazilian individuals with SMD-CRD
from two families by whole-exome sequencing. The study
was approved by the Ethics Committee of Hospital das
Clı´nicas da Faculdade de Medicina da Universidade de
Sa˜o Paulo and informed consent was obtained prior to
the collection of the samples. Family 1 comprises a pair
of siblings whose parents are first-degree cousins: a
17-year-old boy (F1.1, IV-4 in Figure 1), who was born at
term with a birth weight (BW) of 2,900 g and an unre-
corded birth length (BL) and a 2-year-old girl (F1.2, IV-5
in Figure 1) who was born at term with a BW of 2,645 g
and a BL of 44 cm. Both presented with visual impairment
beginning in infancy that progressed to dramatically
reduced visual acuity (hand movements only) along with
short stature and bowing of the legs (Figure 2). A radio-
graphic evaluation of these cases at our service at the
ages of 2 and 17 years disclosed platyspondyly, with scoli-
osis in the older sibling, shortened long bones, generalized
metaphyseal flaring, cupping and presence of spurs in the
lateral and medial distal femur, and mild involvement of
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The Amerlogic evaluation in the older sibling revealed microphthal-
mia, a lack of fixed gaze, strabismus, nystagmus, corneal
opacity in the right eye, corectopia and subluxation of
the lens in the left eye, bilateral coloboma of the optic
nerve, severe macular atrophy, and areas of choroidal and
retinal atrophy (Figure 3A2). No electrical activity was
detectable by a full-field electroretinogram (ERG)
(Figure 3C2). His younger sister presented with very similar
findings: pronounced microphthalmia, nystagmus, stra-
bismus, inferonasal corectopia with subluxated lenses in
both eyes, coloboma of optic nerve, severe macular atro-
phy, and areas of choroidal and retinal atrophy (Table
S1). The cognitive development of both siblings was
adequate, and they do not have facial dysmorphisms.
The lipid profiles of the siblings showed that only the older
brother had mildly reduced levels: triglycerides (TG) of 70
and 149 mg/dl in F1.1 and F1.2, respectively, and total
cholesterol of 107 mg/dl (HDL 36 mg/dl) and 156 mg/dl
(HDL 27 mg/dl). Abdominal ultrasonograms were normal
in both cases.
Family 2 comprises two distant cousins, both products of
consanguineous marriages: an 11-year-old girl (F2.1, V-5 in
Figure 1), born at term with BW of 2,800 g and an unre-
corded BL and a 14-year-old girl (F2.2, V-2 in Figure 1)
born at term with a BWof 2,250 g and a BL of 45 cm. These
individuals presented with progressive lower limb bowing
since the age of 1 year (Figure 2), severe short stature,
normal cognitive development, no facial dysmorphisms,
and low myopia with no complaint of visual impairment.
Both had initially normal fundoscopies. They were evalu-
ated in our service at the ages of 11 and 14 years and ae de Medicina da Universidade de Sa˜o Paulo, Sa˜o Paulo 05403-000, Brazil;
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Figure 1. Pedigrees, PCYT1A Mutations Identified, and Protein Structure
(A) Family pedigrees showing parental consanguinity and PCYT1A mutation segregation within both families, demonstrating auto-
somal-recessive inheritance.
(B) Sequencing chromatograms showing the two different mutations found in PCYT1A: RefSeq NM_005017.2: c.385G>A (p.Glu129Lys)
(family 1) and c.968dupG (p.Ser323Argfs*38) (family 2).
(C) Schematic representation of CCTA showing the mutated residues: in family 1, a mutation was identified that alters an amino acid in
the catalytic domain, and in family 2, a mutation was identified causing a premature truncation in the phosphorylation domain.skeletal survey showed similar abnormalities to those
observed in family 1 (Figure 2). Because these skeletal
findings were highly suggestive of SMD-CRD, an ophthal-
mologic reevaluation was performed and provided the
following results: retinography with reduced foveal bright-
ness without atrophy (Figure 3A1) and visual acuities of
20/20 in both eyes in F2.1 and 20/30 OD, 20/40 OS in
F2.2. An examination of optical coherence tomography
(OCT) showed thinning of the retina in themacular region
of both of individual F2.2’s eyes (Figure 3B). ERG was
possible only in F2.2; in this person, we observed that
the scotopic response was at the lower limit of normality
and that the waves in the photopic phase were strongly
reduced, featuring a cone dysfunction (Figure 3C1). The
plasma lipid profile in these cases showed mildly reduced
levels: TG of 80 and 33 mg/dl in F2.1 and F2.2 and total
cholesterol of 141 mg/dl (HDL 21 mg/dl) and 121 mg/dl
(HDL 31 mg/dl), respectively. An abdominal ultrasono-
gram revealed a diffuse hyperechogenic liver texture,
compatible with increased lipid content in F2.1 and the
presence of gallbladder stones in F2.2.
Exome sequencing of genomic DNA obtained from the
peripheral blood of the four affected individuals was per-
formed with Illumina’s TrueSeq kits for library preparation114 The American Journal of Human Genetics 94, 113–119, January 2and exome capture and the Illumina HiScan sequencer.
Alignment was made with the Burrows-Wheeler Aligner
(BWA),5 and the Genome Analysis Tool Kit (GATK)6 was
used for data processing and variant calling. Variant anno-
tation was performed with ANNOVAR.7 Variants were
filtered for a frequency of less than 1% in the control pop-
ulations (1000 Genomes and 6500 Exome Sequencing
Project from Washington University) and for an allele fre-
quency of less than 5% among 62 Brazilians with different
diseases sequenced in our service.
Because SMD-CRD is known to have a recessive mode
of inheritance and both families show consanguinity,
we hypothesized that homozygous mutations were the
most likely genetic cause. There were initially 20,160
and 17,341 variants in families 1 and 2, respectively;
after filtering, we were left with 18 variants in 15 genes
in family 1 and 17 variants in 7 genes in family 2
(Table S2). The only gene with filtered variants in homo-
zygosity shared by both families was PCYT1A (MIM
123695; RefSeq accession number NM_005017.2). Sur-
rounding PCYT1A, at 3q39, all the affected individuals
also had overlapping large blocks of homozygosity
(chr3: 193,210,768–197,880,134 in family 1 and ch3:
192,053,274–197,236,838 in family 2)., 2014
Figure 2. Clinical Images of F1.2 at 4 Months, F2.1 at 11 Years, and F1.1 at 17 Years
Rhizomelic short limbs with prominent joints are evident in F1.1 and strikingly bowed lower limbs are observed in all three individuals.
Radiographs of F1.2 (7-month-old girl), F2.1 (11-year-old girl), and F1.1 (17-year-old boy): profile and anteroposterior (AP) views of the
spine; AP view of the pelvis; AP view of the lower limbs; AP view of the upper limbs; AP view of the hands. Note the platyspondyly asso-
ciated with ovoid vertebral bodies (F1.2) and anterior wedging (F2.1). Scoliosis may develop in older individuals (F1.1). A narrow sac-
rosciatic notch (F1.2) and coxa vara (F2.1 and F1.1) are disclosed in the pelvis. There is a generalized shortening of the long bones
with widened and irregular metaphyses. Lateral and medial spurs in the distal femur with enlarged epiphyses are evident in F2.1. Pro-
gressive bowing deformity in the lower legs is striking. Mildly shortened metacarpals and phalanges are observed in all individuals.Subjects F1.1 and F1.2 were homozygous for a c.385G>A
(p.Glu129Lys) mutation, and subjects F2.1 and F2.2
were homozygous for a c.968dupG (p.Ser323Argfs*38)
mutation. These mutations were confirmed by Sanger
sequencing in the affected individuals and were identified
in heterozygosity in their respective parents (Figure 1).
Both are predicted to be deleterious by in silico analysis
by Mutation Taster, SIFT, LRT, and PolyPhen2.
PCYT1A encodes for the enzyme choline-phosphate
cytidylyltransferase A (CCT A), which is responsible for
transforming phosphate-choline (P-choline) into cytidine-
diphosphate-choline (CDP-choline) inglycerophospholipid
metabolism. This enzyme exerts a key rate-limiting step in
the CDP-choline pathway, the major pathway in the phos-
phatidylcholine (PC) biosynthesis, comprised of three steps
(Figure S1).8 The ubiquitous and best-studied isoform of
mammalian CCT (CCT A, 367 residues), which functions
as ahomodimer, has beendescribed ashaving four domains:
anN-terminal domain (75 residues) that contains its nuclear
localization signal (NLS) sequence followed by a 150-residue
catalytic domain, a 60-residue membrane binding domain
(domainM), and a 50-residue unstructured phosphorylated
tail that is known to house up to 16 phosphoserine sites,
with unknown function (domain P) (Figure 1C).9–11 The
missensemutation in family 1 (c.385G>A) causes a substitu-
tion (p.Glu129Lys) in a highly conserved amino acid in the
catalytic domain (domain C), most probably altering the
conformation of the region that is important for binding
the nucleotide for phosphorylation.12 Site-directed muta-
genesis in conserved motifs of the catalytic domain hasThe Amerbeen demonstrated to result in highly destructive effects
on enzymatic activity.13 However, it is unclear how the
c.968dupGmutation (family 2), which is predicted to result
in a slightly truncated protein (p.Ser323Argfs*38), might
exert effects, because nonsense-mediated RNA decay is un-
likely.14 In addition, constructs containing deletions of the
phosphorylation domain and substitutions of the serine
amino acids were shown to have no effect on enzymatic
activity or cell proliferation in vitro.9,15
The precise mechanism of how these mutations have
an impact on bone and/or cartilage and retina is currently
unknown, and future functional studies are required to
uncover its exact role. Nevertheless, some data from exper-
iments in tissues and animal models available in the liter-
ature provide some speculative ideas of how this could be
occurring. Pathogenicity could derive either from lack of
PC in specific cells or from increased levels of acetylcholine
(ACh) and ACh receptor activation.
Phospholipids play an important role in maintaining
membrane stability. PC is the major phospholipid compo-
nent of the eukaryotic plasma membrane external leaflet,
which includes the matrix vesicles, and is responsible for
initiating extracellular mineral formation.16,17 Previously,
loss-of-function mutations in CHKB (MIM 612395), one
of the two genes that encode choline kinase (CK), along
with CHKA (MIM 118491), were identified as the cause of
muscular dystrophy with mitochondrial structural abnor-
malities (MIM 602541), the only genetic disorder in hu-
mans that has been associated with deregulation of the
PC pathway. The same mechanisms that were proposedican Journal of Human Genetics 94, 113–119, January 2, 2014 115
Figure 3. Ophthalmological Evaluation of F2.2 and F1.1
Shown are retinography (A), OCT (B), and full-field ERG (C). In the retinography, F2.2 presents only decreased macular brightness and
mild pigmentary changes in the fovea bilaterally (A1). Despite this mild phenotype, decreased macular thickness is evident in the OCT
(B), and there is a severely reduced photopic response in ERG with the scotopic response being at the lower limit of normality (C1). A
severe phenotype with vascular narrowing, and RPE and macular atrophy (A2, top) is associated with eye malformations (coloboma of
the optic nerve) in F1.1 (A2, bottom). No electrical activities were detectable in the full-field ERG (C2).by the authors to be responsible for muscular dystrophy
may be applied to SMD-CRD, i.e., decreased levels of PC
and altered phosphatidylcholine/phosphatidylethanol-
amine (PC/PE) ratios, as well as a different pattern of fatty
acid composition in the PC. Moreover, tissue specificity
was also demonstrated in the study of Mitsuhashi et al.18
because in muscles, only the CKB isoform was present;
CKA was not detectable.19 In our cases, a tissue-specific
pattern may also be operating because a second enzyme,
CCT B, encoded by the PCYT1B gene (MIM 604926) and
expressed as two isoforms (CCT B1 and CCT B2), seems
to have the same function as CCT A. A lack of complete
redundancy between CCT A and CCT B was demonstrated116 The American Journal of Human Genetics 94, 113–119, January 2by the discordant phenotypes of Pcyt1a knockout mice,
which showed early embryonic lethality,20 and the Pcyt1b
knockout mice, which had only gonadal dysfunction and
impaired axonal branching.16
Although no skeletal or retinal abnormalities were
observed in the affected individuals with muscular dystro-
phy, the rmd spontaneous mutant mice, which present a
deletion in Chkb and the same muscle phenotype as hu-
mans, were also visibly smaller than their nonaffected lit-
termates and showed an outward rotation of the forelimbs
caused by severe long bone bowing; this suggests that the
deregulation of the CDP-choline pathway can have an
impact on bone formation.19, 2014
Decreased levels of PC may also be associated with the
mildly reduced levels of TG and total cholesterol that were
observed in our adolescent individuals and the increased
lipid content in the liver of F2.1. This has been demon-
strated in rats fed a choline-deficient diet that resulted in
decreased levels of PC, the accumulation of TG in the liver,
and the impaired secretion of VLDL and LDL, but not HDL
cholesterol, with a reduction of their plasmatic levels.21
On the other hand, not only a decrease in PC product,
but also an excess of substrates, ultimately leading to an
increase in ACh, may be involved in the pathogenesis of
SMD-CRD. In the past two decades, the characterization
of a nonneuronal cholinergic system22 has been proposed.
Several groups have demonstrated that not only neurons,
but different types of cells in several tissues, including
retina, cartilage, and bone, express the complete acetyl-
choline pathway, responsible for an autocrine or paracrine
tissue-specific cholinergic signaling.23,24 Unpublished data
from our laboratory confirm that all the genes in the
acetylcholine pathway are expressed in preosteoblasts
derived from mesenchymal cells. ACh acts as a signaling
molecule, controlling basic cell functions such as prolifer-
ation, differentiation, and the establishment and mainte-
nance of cell-cell contacts. ACh exerts its action by binding
to muscarinic or nicotinic receptors (nAChRs). The latter
are members of a superfamily of ligand-gated ion channels
and play an important physiological role by supplying
ionic signals, including calcium.22,24–26 There is evidence
for the presence of alpha7 nicotinic acetylcholine receptor
(alpha7nAChR) in the retina pigmented epithelium
(RPE)27 and in cartilage.28 Therefore, we can speculate
that the SMD-CRD phenotype may also be a consequence
of elevated P-choline leading to elevated choline and ulti-
mately acetylcholine levels, which in turn activates ace-
thylcholine receptors (AChRs) in an autocrine or paracrine
manner (among them alpha7nAChR), resulting in calcium
influx and downstream signaling.
Different animal models support the hypothesis of skel-
etal dysplasia resulting from excessive acetylcholine activa-
tion, at least in the embryonic stages. Nicotine is the major
candidate compound that has been implicated in intrauter-
ine growth retardation and skeletal growth retardation in
newborns of tobacco-using mothers. Prenatal nicotine
exposure in mice induces delayed chondrogenesis,
specificallymediatedvia fetal alpha7nAChR, and themech-
anism underlying this process may involve the downregu-
lation of IGF-1 signaling and the inhibition of matrix
synthesis by growth plate chondrocytes. The same matrix
synthesis inhibition is observed in human growth plate
chondrocytes in suspension cultures that are treated with
nicotine.28,29Moreover, long bone and vertebral abnormal-
ities have been demonstrated in chick and rat embryos
exposed toorganophosphates (inhibitors of acetylcholines-
terase, the enzyme that degrades Ach).30–33
In summary, the possible explanations of the effective
mechanisms of the deregulation of PC pathway (decreased
levels of PC and/or increased levels of ACh) leading toThe Amerbone and/or cartilage and retinal disease may include: (1)
an imbalance of calcium itself, because it is of major impor-
tance to bone development and signaling, both in bone
and in the RPE; (2) a loss of cell adhesion caused by cyto-
skeletal disaggregation and induced by muscarinic and/or
nicotinic AChR activation;22,34,35 (3) apoptosis secondary
to decreased PC levels;8,36 and/or (4) a modulation of the
inflammatory response in cartilage caused by the non-
neuronal cholinergic system37 (Figure S1).
All persons that have been described so far with SMD-
CRD present a phenotype comprising uniform skeletal
findings, whose first signs (rhizomelia and bowed lower
limbs) are observed mostly during the first year of life,
and RPE dystrophy, which has amore variable age of onset.
Although the majority of the affected individuals showed
signs in infancy and early childhood, some of them,
including the cousins from family 2, presented ophthal-
mologic abnormalities in late childhood and adolescence.
During development, severe disproportionate short stature
is observed, with a final height of less than 100 cm. Multi-
ple orthopedic interventions were required to correct the
bowed lower limbs in some individuals. The spine abnor-
malities do not require interventions because the scoliosis
is usually mild. The visual loss is progressive, and although
it evolves with stabilization during adolescence, this causes
a significant burden for the affected individuals (Table S1).
Unlike the other cases described in the literature, family
1 in this study showed eye malformations. It remains to be
determined whether these additional findings are part of
the spectrum of PC deregulation or, alternatively, if they
may be caused by mutations in a different gene with a
recessive mode of inheritance, such as mutations in
APOD (Table S2), which encodes for apoliprotein D, a lipid
transporter associated with retinol metabolism.38 Retinol
insufficiency or depletion during embryogenesis is a well-
established cause of congenital eye malformations.39,40
The identification of mutations in PCYT1A as the cause
of SMD-CRD substantiates the hypothesis that, in hu-
mans, a deregulation of the choline pathway is respon-
sible, not only for muscular dystrophy, but also for skeletal
and retinal abnormalities. Although we speculated on how
the deregulation of the pathway could interfere with bone
and retinal development, further functional studies are
essential for this confirmation. An increased understand-
ing of this mechanism may lead to better management
of the clinical findings of SMD-CRD, with ultimately pre-
vention of the visual loss.Supplemental Data
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